Scientific journal
Fundamental research
ISSN 1812-7339
"Перечень" ВАК
ИФ РИНЦ = 1,674

Personal portfolio

EFFECTS of erythropoietin IN CLINIC AND EXPERIMENT

Lebedeva Е.А. 1 Beljaevskij А.D. 1 Belousova M.E. 2
1 Rostov state medical university, Rostov-on-Don
2 City hospital first help, Rostov-on-Don
Considering that circumstance that the organism – the self-regulating system, the new direction in therapy of critical conditions is represented use of regulating substances, in norm being produced in the organism. Such substances treats cytokin – erythropoietin (EPO) and its synthetic analog – recombinant EPO (REPO). The EPO protective function (both in vivo, and in vitro) on influence on апоптоз is proved at ischemic reperfuzionny injury of a myocardium, a kidney and a liver. Iizvestna mechanisms of protective action of EPO or REPO on ischemia – a reperfuziya in other bodies and fabrics, including a brain, a spinal cord, a muscular fabric of vessels, heart. EPO reduces anti-inflammatory cytokines, leads to norm an oxidation-reduction condition, participates in neurogenesis, causes activation of endotelialny NO-sintenasa and prevents cerebral vasospasm, and also reduces NO toxicity. There are the data, testifying that EPO has direct effects of an antioxidant. There are separate messages that among the traumatologic patients being in resuscitation unit, the lethality in group with use of EPO appeared authentically smaller. This fact directs at reflections about the general protective role of EPO on the relation to all vitals and fabrics, allowing to use vneeritropoetichesky effects given a preparation in therapy of critical conditions.
erythropoietin
protective properties
1. Baksheev V.I., Kolomoec N.M. Jeritropojetin v klinicheskoj praktike: proshloe, nastojawee i buduwee (obzor literatury) (Eritropoetin in clinical practice: last, present and future (literature review). Clinical medicina. 2007. no. 9. pp. 30–37.
2. Ermolenko V.M., Nikolaev A.Ju. Jeritropojetin: biologicheskie svojstva i primenenie v klinike (Eritropoetin: biological properties and application in clinic). Therapeutic archive. 1990. Vol. 62. no. 11. pp. 141–145.
3. Zhetiwev R.A. Primenenie Jepokrina v lechenii anemii novorozhdennyh, nahodjawihsja v otdelenii reanimacii i intensivnoj terapii (Epokrin’s application in treatment of anemia of the newborns being in office of reanimation and intensive therapy). Fundamental and applied problems of biotechnology and medicine: materials of scientifically technical conference. St. Petersburg. 2000. pp. 64–65.
4. Kazarin V.S., Kustov V.M. Primenenie otechestvennogo rekombinantnogo jeritropojetina v ortopedicheskoj hirurgii. (Application domestic recombinant erythropoietin in orthopedic surgery) Fundamental and applied problems of biotechnology and medicine: materials of scientifically technical conference. St. Petersburg. 2000. pp. 65–66.
5. Ketlinskij S.A., Simbircev A.S. Citokiny. – SPb.: OOO «Izdatel’stvo Foliant», 2008. 552 р.
6. Pavlov A.D., Morwakova E.F., Rumjancev A.G. Jeritropojetin: otkrytija i dostizhenija (Eritropoetin: opening and achievements). Medical newspaper. 2006. no. 65.
7. Samarina A.V., Sineva S.A. Primenenie rekombinantnogo jeritropojetina cheloveka u beremennyh i rodil’nic s anemiej (Application recombinant erythropoietin at pregnant women and women in childbirth with anemia). Fundamental and applied problems of biotechnology and medicine: materials of scientifically technical conference. St. Petersburg. 2000. pp. 71.
8. Shilov A.M., Mel’nik M.V., Sarycheva A.A. Anemii pri serdechnoj nedostatochnosti (Anemias at warm insufficiency). The Russian medical magazine. 2003. Vol. 11. no. 9. pp. 545.
9. Agnello D., Bigini P., Villa P., Mennini T., Cerami A., Brines M.L., Ghezzi P. Brain Res. 2002. no. 952. рр. 128–134.
10. Akimoto T., Kusano E., Inaba T., Iimura O., Takahashi H., Ikeda H., Ito C., Ando Y., Ozawa K., Asano Y. Kidney Int. 2000. no. 58. рр. 269–282.
11. Bauer С. Erythropoietin – from gene structure to therapeutic applications. J. Perinat. Med. 1995. Vol. 23. no. 1–2. рр. 77–81.
12. Bernaudin M., Bellail A., Marti H.H., Yvon A., Vivien D., Duchatelle I., Mackenzie E.T., Petit E. Glia. 2000. Vol. 30. no. 3. рр. 271–278.
13. Bogoyevitch M.A. An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc. Res. 2004. Vol. 63. no. 2. рр. 208–216.
14. Buemi M., Cavallaro E., Floccari F., Sturiale A., Aloisi C., Trimarchi M., Grasso G., Corica F., Frisina N. Clin Science. 2002. Vol. 103. no. 3. рр. 275–282.
15. Buemi M., Caccamo C., Nostro L., Cavallaro E., Floccari F., Grasso G. Med. Res. Rev. 2005. Vol. 25. no. 2. рр. 245–259.
16. Cai Z., Manalo D.J., Wei G., Rodriguez E.R., Fox-Talbot K., Lu H., Zweier J.L., Semenza G.L. Circulation. 2003. Vol. 108. no. 1. рр. 79–85.
17. Calvillo L., Latini R., Kajstura J., Leri A., Anversa P., Ghezzi P., Salio M., Cerami A., Brinеs M. Proc. Natl. Acad. Sci. USA. 2003. Vol. 100. no. 8. рр. 4802–4806.
18. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ. 1990. Vol. 300. no. 6724. рр. 573–578.
19. Chong Z.Z., Kang J.Q., Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation. 2002. Vol. 106. no. 23. рр. 2973–2979.
20. Corwin H.L., Gettinger A., Fabian T.C., May A., Pearl R.G., Heard S., An R., Bowers P.J., Burton P., Klausner M.A., Corwin M.J. N. Engl. J. Med. 2007. Vol. 357. no. 10. рр. 1037–1039.
21. Danco J., Huch R., Huch A. Epoietin alfa for treatment of postpartum anaemia. Lancet. 1990. Vol. 335. рр. 737–738.
22. Digicaylioglu M., Lipton S. A. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-B signalling cascades. Nature. 2001. Vol. 412. рр. 641–647.
23. Fantacci M., Bianciardi P., Caretti A. Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia. Proc. Natl. Acad. Sci. USA. 2006. Vol. 103. no. 46. рр. 17531–17536.
24. Grimm C., Wenzel A., Acar N., Keller S., Seeliger M., Gassmann M. Adv Exp Med Biol. 2006. Vol. 588. рр. 119–131.
25. Hasselblatt M., Ehrenreich H., Siren A.L. The brain erythropoietin system and its potential for therapeutic exploitation in brain disease. J. Neurosurg. Anesthesiol. 2006. Vol. 18. no. 2. рр. 132–138.
26. Heeschen C., Aicher A., Lehmann R., Fichtlscherer S., Vasa M., Urbich C., Mildner-Rihm C., Martin H., Zeiher A.M., Dimmeler S. Blood. 2003. no. 102. рр. 1340–1346.
27. Juul S. Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr. Suppl. 2002. Vol. 91. no. 438. рр. 36–42.
28. Kumral A., Baskin H., Yesilirmak D.C., Ergur B.U., Aykan S., Genc S., Genc K., Yilmaz O., Tugyan K., Giray O., Duman N., Ozkan H. Neonatology. 2007. Vol. 92. no. 4. рр. 269–278.
29. Ludwig H., Fritz E., Kotzmann H., Hocker P., Gisslinger H., Barnas U. N. Engl. J. Med.. 1990. Vol. 322. no. 24. pp. 1693–1699.
30. Manolis A.S., Tzeis S., Triantafyllou K., Michaelidis J., Pyrros I., Sakellaris N., Kranidis A., Melita H. Curr. Drug Targets Cardiovasc. Haematol. Disord. 2005. Vol. 5. no. 5. pp. 355–375.
31. Marti H.H. Erythropoietin and the hypoxic brain. J. Exp Biol. 2004. Vol. 207. no. 18. pp. 3233–3242.
32. Marti H.H., Bernaudin M., Petit E., Bauer C. News Physiol. Sci. 2000. Vol. 15. pp. 225–229.
33. Masuda S., Chikuma M., Susaki R. Insulinlike growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes. Brain Res. 1997. no. 745. pp. 63–70.
34. Melli G., Jack C., Lambrinos G.L., Ringkamp M., Hoke A. Neurobiol Dis. 2006. Vol. 24. no. 3. pp. 525–530.
35. Miller C.B., Jones R.J., Piantadosi S., Abeloff M.D., Spivak J.L. N. Engl. J. Med. 1990. Vol. 322. no. 24. рр. 1689–1692.
36. Moore E.M., Bellomo R., Nichol A.D. Erythropoietin as a novel brain and kidney protective agent. Anaesth. Intensive Care. 2011. Vol. 39. no.3. рр. 356–372.
37. Oster W., Herrmann F., Cicco A. Erythropoietin prevents chemotherapy-induced anemia: case report. Blut. 1990. Vol. 60. no. 2. рр. 88–92.
38. Santhanam A.V., Katusic Z.S. Erythropoietin and cerebral vascular protection: role of nitric oxide. Acta Pharmacol. Sin. 2006. Vol. 27. no. 11. рр. 1389–1394.
39. Sepodes B., Maio R., Pinto R., Sharples E., Oliveira P., McDonald M., Yaqoob M., Thiemermann C., Mota-Filipe H. Transpl. Int. 2006. Vol. 19. no. 11. рр. 919–926.
40. Shingo T., Sorokan S.T., Shimazaki T., Weiss S. J. Neurosci. 2001. Vol. 21. no. 24. рр. 9733–9743.
41. Siren A.L., Fratelli M., Brines M., Goemans C., Casagrande S., Lewczuk P., Keenan S., Gleiter C., Pasquali C., Capobianco A., Mennini T., Heumann R., Cerami A., Ehrenreich H., Ghezzi P. Proc. Natl. Acad. Sci. USA. 2001. Vol. 98. no. 7. рр. 4044–4049.
42. Spivak J.L. Serum immunoreactive erythropoietin in heals and disease. J. Perinat. Med. 1995. Vol. 23. no. 1–2. рр. 13–17.
43. Sun Y., Zhou C., Polk P., Nanda A., Zhang J.H. J. Cereb. Blood. Flow. Metab. 2004. Vol. 24. no. 2. рр. 259–270.
44. van der Meer P., Lipsic E., Henning R.H., Boddeus K., van der Velden J., Voors A.A., van Veldhuisen D.J., van Gilst W.H., Schoemaker R.G. J. Am Coll. Cardiol. 2005. Vol. 46. no. 1. рр. 125–33.
45. Vesey D.A., Cheung C., Pat B., Endre Z., Gobe G., Johnson D.W. Nephrol. Dial. Transplant. 2004. Vol. 19. no. 2. рр. 348–355.
46. Villa P., Bigini P., Mennini T., Agnello D., Laragione T., Cagnotto A., Viviani B., Marinovich M., Cerami A., Coleman T.R., Brines M., Ghezzi P. J. Exp. Med. 2003. Vol. 198. no. 6. рр. 971–975.
47. Wang L., Zhang Z., Wang Y., Zhang R., Chopp M. Stroke. 2004. Vol. 35. no. 7. рр. 1732–1737.
48. Wright G.L., Hanlon P., Amin K., Steenbergen C., Murphy E., Arcasoy M.O. FASEB J. 2004. Vol. 18. no. 9. рр. 1031–1033.
49. Wu H., Lee S.H., Gao J., Liu X., Iruela-Arispe M.L. Development. 1999. Vol. 126. no. 16. рр. 3597–3605.
50. Yang C.W., Li C., Jung J.Y., Shin S.J., Choi B.S., Lim S.W., Sun B.K., Kim Y.S., Kim J., Chang Y.S., Bang B.K. FASEB. J. 2003. Vol. 17. no. 12. рр. 1754–1755.

Рецензенты:

Женило В.М., д.м.н., профессор, заведующий кафедрой анестезиологии и реаниматологии № 1 ГБОУ ВПО «Ростовский государственный медицинский университет» Минздравсоцразвития, г. Ростов-на-Дону;

Ушакова Н.Д., д.м.н., профессор, заведующая отделением гемодиализа и экстракорпоральных методов лечения ФГБУ «РНИОИ Минздравсоцразвития РФ», г. Ростов-на-Дону.